Real-World Clinical Experience of Rosuvastatin as a Lipid-Lowering Therapy for Primary and Secondary Prevention of Cardiovascular Events (REAL ROSE)

• Published in: Curēus (Palo Alto, CA) Vol. 14; no. 11; p. e31468
• Main Authors: Mehta, Ashwani, Jain, Pradeep, Patil, Ravikant, Sashi Kant, T, Indurkar, Sanjiv A, Kota, Sunil Kumar, Revankar, Santosh, Gupta, Amit
• Format: Journal Article
• Language: English
• Published: United States Springer Nature B.V 14.11.2022; Cureus
• Subjects: Acute coronary syndromes; Aspirin; Atherosclerosis; Body mass index; Cardiology; Cardiovascular disease; Cholesterol; Coronary vessels; Demographics; Diabetes; Disease prevention; Enzymes; Ethics; Family medical history; High density lipoprotein; Internal Medicine; Lipids; Medical records; Metabolic disorders; Mortality; Observational studies; Preventive Medicine; Risk factors; Statins; Vein & artery diseases; India; dose titration; dyslipidemia; high-intensity; rosuvastatin; statins
• ISSN: 2168-8184; 2168-8184
• DOI: 10.7759/cureus.31468

Background Rosuvastatin effectively reduces endogenous cholesterol synthesis and low-density lipoprotein (LDL) cholesterol and increases high-density lipoprotein (HDL) cholesterol. This study aimed to evaluate the clinical characteristics of patients and treatment patterns of rosuvastatin as a lipid-lowering therapy for primary and secondary prevention of cardiovascular events in Indian settings. Methods This real-world, retrospective multi-centric observational study included patients aged >18 years who received treatment with a rosuvastatin/rosuvastatin-based combination. Demographic and data about concomitant diseases and medications were recorded. Results Out of 1,816 patients, the majority were men (66.2%); the mean age was 54.1 years. The patients prescribed rosuvastatin for primary and secondary prevention of cardiovascular events were 71.9% and 28.1%, respectively. Rosuvastatin 10 mg (56.8%) was the most commonly prescribed dose. For primary prevention, 10 mg (65.0%) was the most preferred dose, and for secondary prevention, 20 mg (54.3%) was the most preferred dose. Rosuvastatin treatment significantly (pre- vs. post-treatment) reduced the levels of total cholesterol (227.2 vs. 178.4 mg/dL), triglycerides (212.6 vs. 154.4 mg/dL), and LDL cholesterol (167.0 vs. 125.6 mg/dL), and increased HDL cholesterol levels (40.7 vs. 44.3 mg/dL) (p<0.0001). A total of 1,196 patients received combination therapy with rosuvastatin (aspirin, 34.0%, and fenofibrate, 21.9%). Adverse events were reported in 0.4% of the study population (leg pain, nausea, muscle cramps/pain, bleeding, and myalgia). Conclusion This study demonstrated the clinical effectiveness and safety of moderate- to high-intensity rosuvastatin (5-40 mg) for primary and secondary prevention of cardiovascular events in the Indian population. A primary prevention strategy with statins can reduce cardiovascular events and associated morbidity and mortality.